Windtree Therapeutics Inc (WINT) - News Archive

Windtree Therapeutics Regains Compliance with Nasdaq Listing RulesWARRINGTON, Pa. In a significant turnaround for Windtree Therapeutics, Inc. (NasdaqCM: WINT), the biotechnology firm announced on March 24, 2025, that it...

Reverse Stock Split Announced by Windtree Therapeutics: Analyzing the Strategic MoveIn a notable development for Windtree Therapeutics, Inc. (NasdaqCM: WINT), the company s board of directors has given the green light t...

: Istaroxime, a novel therapeutic agent, has demonstrated promising efficacy in a Phase 2b study focusing on acute heart failure patients experiencing early cardiogenic shock. This article consolidates findings from rec...

Heart failure, particularly in the context of early cardiogenic shock (ECS), represents a critical condition affecting millions globally. Traditional treatments have often struggled to effectively manage the complexitie...

In the annals of medical advancement, one can scarcely overlook the titanic struggles and triumphs that bespeak the human endeavour to alleviate suffering. It is with a spirit of anticipation that we herald the promisin...

Windtree Therapeutics Inc. recently achieved a significant milestone by completing enrollment in its Phase 2b study of Istaroxime, a potential treatment for early cardiogenic shock. While the anticipation for topline da...

Amidst the ever-changing landscape of the healthcare sector, Windtree Therapeutics Inc (NASDAQ: WINT) has emerged as a key player with a potential for future returns. This Philadelphia-based biopharmaceutical company sp...

Windtree Therapeutics Advances Istaroxime Clinical Development with Promising Data Expected from SEISMiC Extension Phase 2b Study in Early Cardiogenic Shock Patients Windtree Therapeutics has made significant strides in...

Windtree Therapeutics Completes $12.9 Million Transaction with New Funding and Full Cancellation of Outstanding Senior NotesWindtree Therapeutics has recently announced the successful completion of a $12.9 million trans...

In a recent press release, biotechnology company Windtree Therapeutics (NASDAQ: WINT) has announced a 1-for-18 reverse stock split, effective April 19, 2024. The company s common stock will trade on The Nasdaq Capital M...

Windtree Therapeutics, Inc. has recently made significant advancements in its operations within the biotechnology and pharmaceutical industries. On April 2, 2024, the company entered into an asset purchase agreement wit...

WARRINGTON, Pa., Feb. 01, 2024 - Windtree Therapeutics, a prominent biotechnology company focusing on late-stage interventions for critical cardiovascular disorders, has recently announced the renewal of its partnership...

Ladenburg Thalmann & Co. Engaged to Assess Strategic Alternatives for Windtree Therapeutics Inc., Maximizing Stockholder ValueWARRINGTON, Pa., Jan. 31, 2024 - Windtree Therapeutics, Inc. (Windtree or the Company) (Nasda...

In a recent press release, Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced a significant development in its efforts to advance interventions for critical cardiovascular disorders. The biotechnology company reveal...

In an exciting development, Windtree Therapeutics, a biopharmaceutical company specializing in the development of innovative therapeutics for cardiovascular and respiratory diseases, has announced a strategic license ag...

In recent years, there have been significant advancements in the field of cardiovascular medicine, particularly in the treatment of arrhythmias. Windtree Therapeutics, a leading biotechnology company, has announced impr...

In the realm of medical advancements, every breakthrough offers new hope for patients and medical professionals alike. One such breakthrough is being pioneered by Windtree Therapeutics, a biotechnology company specializ...

Windtree Therapeutics, a renowned biotechnology company, has recently announced the issuance of a groundbreaking patent for a new class of SERCA2a Activators. This development has enormous potential and could revolution...